News Room | BioStrand Company

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue

VICTORIA, BRITISH COLUMBIA (CANADA), April 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”), a group of Belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary ImmunoPrecise Netherlands BV.

BioStrand Acquired by IPA

DIEPENBEEK, BELGIUM, March 29^th, 2022 – BioStrand BV is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to be acquired by IPA (ImmunoPrecise Antibodies Ltd.), through IPA’s wholly-owned subsidiary ImmunoPrecise Netherlands B.V. IPA will gain control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”).

BioStrand secures second VLAIO research grant

Diepenbeek, Belgium - 12 January 2022 - Belgian end-to-end multi-omics analysis platform provider BioStrand has received a €460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. Awarded in January this year, the second grant from VLAIO follows a €235,000 funding awarded in 2020.